Vir Biotechnology, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vir Biotechnology, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.56M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $74.21M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $86.18M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $1.62B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.10B | Feb 26, 2024 |
| FY2020 | Dec 31, 2020 | $1.73M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $1.93M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $66.99M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $5.72M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $980.0K | Feb 25, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.56M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $74.21M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $86.18M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $1.62B | Feb 27, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($437.99M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($521.96M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($615.06M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $515.84M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $528.58M | Feb 26, 2024 |
| FY2020 | Dec 31, 2020 | ($105.65M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($84.61M) | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($31.17M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($77.24M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | ($63.77M) | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($479.33M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($587.17M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($684.31M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $833.07M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $420.75M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($296.98M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($177.98M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($118.69M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($81.50M) | Mar 26, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $455.97M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $506.50M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $579.72M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $474.65M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $448.01M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $302.41M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $148.47M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $100.23M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $62.51M | Mar 26, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $92.07M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $119.03M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $174.44M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $161.76M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $160.79M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $70.94M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $37.60M | Feb 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($391.78M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($446.35M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | ($778.79M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $1.66B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($47.59M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($190.94M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | ($129.63M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($94.10M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($66.38M) | Mar 26, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.83M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $7.30M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $21.57M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $68.01M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $21.82M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $6.55M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $8.94M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $8.19M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $2.74M | Mar 26, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.00B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $1.40B | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $1.92B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.80B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.95B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $918.76M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $512.07M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $191.60M | Mar 26, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $237.55M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $248.43M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $328.82M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $724.13M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $522.42M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $201.91M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $88.13M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $61.64M | Mar 26, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.08B | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $1.43B | Feb 28, 2023 |
| FY2022 | Dec 31, 2020 | $716.85M | Feb 28, 2023 |
| FY2022 | Dec 31, 2019 | $423.94M | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | ($179.18M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | ($68.92M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | ($7.97M) | Mar 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.94M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $16.94M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $16.94M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $16.94M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $16.94M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $16.94M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $16.94M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $16.94M | Mar 26, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.20B) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($759.78M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($237.82M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $377.24M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($138.60M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($667.18M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($368.52M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($193.84M) | Mar 26, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $232.19M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $222.95M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $241.58M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $848.63M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $347.82M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $436.58M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $109.34M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $47.60M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $187.92M | Mar 26, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 26, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 3 | Feb 26, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 139.47M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 136.96M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | 134.78M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 133.24M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 131.16M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 127.42M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 107.65M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 8.86M | Mar 26, 2020 |